Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach... Show more
CRON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 27 cases where CRON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on November 26, 2025. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CRON moved below its 50-day moving average on November 11, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CRON entered a downward trend on November 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.877) is normal, around the industry mean (16.611). P/E Ratio (22.591) is within average values for comparable stocks, (73.365). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.952). CRON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (7.184) is also within normal values, averaging (55.743).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
pharmaceutical, medical marijuana, cannabis
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | -0.40% | ||
| SNDL - CRON | 73% Closely correlated | +1.15% | ||
| TLRY - CRON | 66% Closely correlated | -21.07% | ||
| CGC - CRON | 61% Loosely correlated | -3.31% | ||
| OGI - CRON | 60% Loosely correlated | +1.86% | ||
| ACB - CRON | 60% Loosely correlated | +0.22% | ||
More | ||||
| Ticker / NAME | Correlation To CRON | 1D Price Change % |
|---|---|---|
| CRON | 100% | -0.40% |
| CRON (2 stocks) | 90% Closely correlated | -10.74% |
| Pharmaceuticals: Generic (213 stocks) | 36% Loosely correlated | +0.54% |